Dexmedetomidine (Cepedex) added to the Aesculaap Private Label

Dexmedetomidine (Cepedex) added to the Aesculaap Private Label
23/09/2021

Cepedex 0.5 mg/ml is the newest anesthetic for dogs and cats in the Aesculaap Private Label. Cepedex is indicated for both sedation and premedication in these animals.

Cepedex has as active ingredient dexmedetomidine, an alpha2 agonist. This substance attaches to the alpha2-adrenergic receptors and thus prevents the release of the neurotransmitter noradrenaline in nerve cells. This results in a lower level of consciousness, including a reduced perception of pain.

Dexmedetomidine offers the advantages but not the disadvantages of its predecessor medetomidine (Cepetor). Where medetomidine consists of a racemic mixture of approximately 50% dexmedetomidine (the active component) and 50% levomedetomidine (inactive), Cepedex contains only dexmedetomidine. Pure and effective! As a result, the animal is not burdened with non-active ingredients.

Cepedex can be administered intravenously or intramuscularly in dogs; in cats intramuscularly. It is safe to combine with butorphanol and/or ketamine in the same syringe. Cepedex is quickly and effectively antagonized with atipamezole (Revertor). The dosage of dexmedetomidine is only half that of medetomidine. The concentration of Cepedex is intentionally 0.5 mg/ml, half the concentration of medetomidine. This way the volumes to be given are close to each other, which is very safe!

More information can be found in the Cepedex product information and leaflet.